Hemab Therapeutics Holdings COAG
NASDAQ COAG
$40.86 +1.48 (+3.76%)
At close: Nov 13, 2026 · 4:00 PM EST

Hemab Therapeutics Holdings (COAG) Return on Capital Employed [ROCE] (2026)

Updated

Hemab Therapeutics Holdings (COAG) posted Return on Capital Employed [ROCE] of -21.82% for Q3 2026, up 5.02 percentage points from the prior quarter.

Analysis

Hemab Therapeutics Holdings (COAG) Return on Capital Employed [ROCE] (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 17.52%
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 21.60%
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 4.65%
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 9.91%
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 17.37%
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -6.15%
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 11.32%
10 Hemab Therapeutics Holdings 1.91 Bn 672.70 Mn - -21.82%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -21.82%
Jun 30, 2026 -26.83%
Mar 31, 2026 -42.65%
API Access

Hemab Therapeutics Holdings Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=COAG&period=max&api_key=YOUR_API_KEY